Company intelligence / Profile preview

Osiris Therapeutics, Inc.

Columbia, Maryland, United Statesghostproductions.com ↗

Ownership: Public · OSIR
Employees: ~161
Development stage: Commercial

Overview

Osiris Therapeutics developed the world's first approved stem cell drug (Prochymal/remestemcel-L) for pediatric Graft-versus-Host Disease. The company achieved commercial success with products in orthopedics, sports medicine, and wound care, including BIO4, Cartiform, and Grafix.

Therapeutic areas: GastroenterologyCardiovascularRheumatologyImmunologyEndocrinologyDermatology
Modalities: Stem CellsCellular TherapiesTissue-based Products
Industry: Biotech

Drug pipeline

4 assets

remestemcel-L

Commercial

Indications: Graft-versus-host disease, Crohn's disease

3 more assets in the full pipeline.

Request access →

Partnerships

Department of Veteran AffairsDepartment of DefenseHowmedica Osteonics Corp.Mesoblast LimitedStryker Corporation

Beyond the preview

Go deeper on Osiris Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Osiris Therapeutics, Inc..

Explore the full profile